• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

间变性淋巴瘤激酶对炎性肌纤维母细胞瘤的潜在诊断作用评估：一项荟萃分析。

Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumours: a meta-analysis.

作者信息

Wu Shuiqing, Xu Ran, Wan Qi, Zhu Xuan, Zhang Lei, Jiang Hongyi, Zhao Xiaokun

机构信息

Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.

Neural Medical Center of the First Hospital in Changsha City, Changsha, China.

出版信息

PLoS One. 2015 Apr 24;10(4):e0125087. doi: 10.1371/journal.pone.0125087. eCollection 2015.

DOI:10.1371/journal.pone.0125087
PMID:25910080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4409171/
Abstract

OBJECTIVE

To assess the value of anaplastic lymphoma kinase for the diagnosis of inflammatory myofibroblastic tumours using a comprehensive meta-analysis.

METHODS

We searched the related literature using electronic databases and manual searches. Approximately 454 cases from several countries were included in this analysis. The quality of studies included was assessed by QUADAS (quality assessment of studies of diagnostic accuracy). The diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), sensitivity and specificity were calculated to assess the role of anaplastic lymphoma kinase in the diagnosis of inflammatory myofibroblastic tumours. The overall test performance was summarised by an SROC (summary receiver operating characteristic curve). The heterogeneity and publication bias were analysed using Meta-regression and Deeks' test. All data were analysed by Stata 12.0 software.

RESULTS

Eight studies were included according to our inclusion criteria. The overall results for the specificity, sensitivity, PLR, NLR, DOR and area under the curve (AUC) were 0.99 (95% CI 0.82-1.00), 0.67 (95% CI 0.46-0.83), 0.67 (95% CI 0.46-0.83), 60.6 (95% CI 3.3-1112.4), 0.33 (95% CI 0.19-0.60), 181 (95% CI 9-3684) and 0.95 (95% CI 0.93-0.97), respectively, while the specificity, sensitivity, PLR, NLR, DOR and AUC for bladder IMTs were 0.99 (95% CI 0.67-1.00), 0.86 (95% CI 0.58-0.96), 95.6 (95% CI 2.0-4616.2), 0.14 (95% CI 0.04-0.50), 671 (95% CI 16-28913) and 0.99 (95% CI 0.97-0.99), respectively.

CONCLUSION

The present meta-analysis indicated that anaplastic lymphoma kinase plays a significant role in the differential diagnosis of inflammatory myofibroblastic tumours, particularly for inflammatory myofibroblastic tumours of the urinary bladder.

摘要

目的

通过全面的荟萃分析评估间变性淋巴瘤激酶在炎性肌纤维母细胞瘤诊断中的价值。

方法

我们使用电子数据库和手工检索来搜索相关文献。本分析纳入了来自几个国家的约454例病例。纳入研究的质量通过QUADAS（诊断准确性研究的质量评估）进行评估。计算诊断比值比（DOR）、阳性似然比（PLR）、阴性似然比（NLR）、敏感性和特异性，以评估间变性淋巴瘤激酶在炎性肌纤维母细胞瘤诊断中的作用。通过汇总受试者工作特征曲线（SROC）总结总体检验性能。使用Meta回归和Deeks检验分析异质性和发表偏倚。所有数据均使用Stata 12.0软件进行分析。

结果

根据我们的纳入标准，纳入了八项研究。特异性、敏感性、PLR、NLR、DOR和曲线下面积（AUC）的总体结果分别为0.99（95%可信区间0.82 - 1.00）、0.67（95%可信区间0.46 - 0.83）、0.67（95%可信区间0.46 - 0.83）、60.6（95%可信区间3.3 - 1112.4）、0.33（95%可信区间0.19 - 0.60）、181（95%可信区间9 - 3684）和0.95（95%可信区间0.93 - 0.97），而膀胱炎性肌纤维母细胞瘤的特异性、敏感性、PLR、NLR、DOR和AUC分别为0.99（95%可信区间0.67 - 1.00）、0.86（95%可信区间0.58 - 0.96）、95.6（95%可信区间2.0 - 4616.2）、0.14（95%可信区间0.04 - 0.50）、671（95%可信区间16 - 28913）和0.99（95%可信区间0.97 - 0.99）。

结论

本荟萃分析表明，间变性淋巴瘤激酶在炎性肌纤维母细胞瘤的鉴别诊断中起重要作用，特别是对于膀胱炎性肌纤维母细胞瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/e10df1bf06c0/pone.0125087.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/4760c845ad9c/pone.0125087.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/acd2fb00547c/pone.0125087.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/0b76d5127b86/pone.0125087.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/c9838deb8eeb/pone.0125087.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/b27c1308934d/pone.0125087.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/2955012894bc/pone.0125087.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/e10df1bf06c0/pone.0125087.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/4760c845ad9c/pone.0125087.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/acd2fb00547c/pone.0125087.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/0b76d5127b86/pone.0125087.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/c9838deb8eeb/pone.0125087.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/b27c1308934d/pone.0125087.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/2955012894bc/pone.0125087.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/101e/4409171/e10df1bf06c0/pone.0125087.g007.jpg

相似文献

1
Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumours: a meta-analysis.间变性淋巴瘤激酶对炎性肌纤维母细胞瘤的潜在诊断作用评估：一项荟萃分析。
PLoS One. 2015 Apr 24;10(4):e0125087. doi: 10.1371/journal.pone.0125087. eCollection 2015.
2
Pleural effusion as a substitute for tumor tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: A systematic review and meta-analysis.胸腔积液作为非小细胞肺癌中检测表皮生长因子受体/间变性淋巴瘤激酶突变的肿瘤组织替代物：一项系统评价和荟萃分析
Medicine (Baltimore). 2019 May;98(18):e15450. doi: 10.1097/MD.0000000000015450.
3
[Diagnostic accuracy of artery peak velocity variation measured by bedside real-time ultrasound for prediction of fluid responsiveness: a Meta-analysis].[床旁实时超声测量动脉峰值速度变化对液体反应性预测的诊断准确性：一项Meta分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Jan;32(1):99-105. doi: 10.3760/cma.j.cn121430-20191226-00018.
4
Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis.膀胱肿瘤纤连蛋白对膀胱肿瘤患者的诊断价值：系统评价与荟萃分析。
Clin Biochem. 2013 Oct;46(15):1377-82. doi: 10.1016/j.clinbiochem.2013.05.064. Epub 2013 Jun 2.
5
Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis.血液和尿液中的游离DNA作为膀胱癌的诊断工具：一项荟萃分析。
Am J Transl Res. 2018 Jul 15;10(7):1935-1948. eCollection 2018.
6
Predictive value of microRNAs as novel biomarkers in detection of lymphoma.微小RNA作为新型生物标志物在淋巴瘤检测中的预测价值
Int J Clin Exp Med. 2015 Aug 15;8(8):14479-89. eCollection 2015.
7
Meta-analysis of diffusion-weighted imaging in the differential diagnosis of renal lesions.扩散加权成像在肾脏病变鉴别诊断中的荟萃分析。
Clin Imaging. 2018 Nov-Dec;52:264-272. doi: 10.1016/j.clinimag.2018.08.010. Epub 2018 Aug 23.
8
16S Ribosomal Ribonucleic Acid Gene Polymerase Chain Reaction in the Diagnosis of Bloodstream Infections: A Systematic Review and Meta-Analysis.16S核糖体核糖核酸基因聚合酶链反应在血流感染诊断中的应用：一项系统评价与Meta分析
PLoS One. 2015 May 21;10(5):e0127195. doi: 10.1371/journal.pone.0127195. eCollection 2015.
9
MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis.微小RNA作为膀胱癌诊断生物标志物的Meta分析
Clin Lab. 2015;61(8):1101-8. doi: 10.7754/clin.lab.2015.150204.
10
Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis.DWI 对原发性中枢神经系统淋巴瘤与胶质母细胞瘤鉴别诊断的性能：系统评价和荟萃分析。
Neurol Sci. 2019 May;40(5):947-956. doi: 10.1007/s10072-019-03732-7. Epub 2019 Jan 31.

引用本文的文献

1
Inflammatory Myofibroblastic Tumor of the Urinary Bladder: An 11-Year Retrospective Study From a Single Center.膀胱炎性肌纤维母细胞瘤：来自单一中心的11年回顾性研究
Front Med (Lausanne). 2022 Mar 3;9:831952. doi: 10.3389/fmed.2022.831952. eCollection 2022.
2
Case report of an unexpected inflammatory myofibroblastic tumor.一例意外发现的炎性肌成纤维细胞瘤病例报告。
Ann Med Surg (Lond). 2021 Apr 22;65:102316. doi: 10.1016/j.amsu.2021.102316. eCollection 2021 May.
3
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.

本文引用的文献

1
Inflammatory myofibroblastic tumor of the bladder.膀胱炎性肌纤维母细胞瘤
Arch Pathol Lab Med. 2014 Oct;138(10):1272-7. doi: 10.5858/arpa.2014-0274-CC.
2
Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review.膀胱炎性肌纤维母细胞瘤：一项系统综述
Urology. 2014 Sep;84(3):503-8. doi: 10.1016/j.urology.2014.05.039.
3
Inflammatory myofibroblastic tumor of the urinary bladder in a patient with the left renal cell carcinoma: A case report.一名左肾细胞癌患者并发膀胱炎性肌纤维母细胞瘤：病例报告
肝细胞癌中一种免疫相关预后预测指标的鉴定
Front Mol Biosci. 2020 Sep 24;7:567950. doi: 10.3389/fmolb.2020.567950. eCollection 2020.
4
The evaluation of monocyte lymphocyte ratio as a preoperative predictor in urothelial malignancies: a pooled analysis based on comparative studies.单核细胞-淋巴细胞比值作为尿路上皮恶性肿瘤术前预测指标的评估：基于比较研究的汇总分析。
Sci Rep. 2019 Apr 18;9(1):6280. doi: 10.1038/s41598-019-42781-y.
Exp Ther Med. 2014 Apr;7(4):1010-1012. doi: 10.3892/etm.2014.1525. Epub 2014 Feb 7.
4
Low-grade myofibroblastic proliferations of the urinary bladder.膀胱低度肌纤维母细胞增生。
Arch Pathol Lab Med. 2013 Aug;137(8):1117-28. doi: 10.5858/arpa.2012-0326-RA.
5
Inflammatory myofibroblastic tumor of the colon.结肠炎性肌纤维母细胞瘤
J Clin Oncol. 2013 Apr 1;31(10):e155-8. doi: 10.1200/JCO.2012.42.8961. Epub 2013 Jan 28.
6
Quantification of Epstein-Barr virus DNA in patients with idiopathic orbital inflammatory pseudotumor.特发性眼眶炎性假瘤患者的 Epstein-Barr 病毒 DNA 定量检测。
PLoS One. 2013;8(1):e50812. doi: 10.1371/journal.pone.0050812. Epub 2013 Jan 2.
7
Primary inflammatory myofibroblastic tumor of the breast with rapid recurrence and metastasis: A case report.乳腺原发性炎性肌纤维母细胞瘤伴快速复发和转移：病例报告
Oncol Lett. 2013 Jan;5(1):97-100. doi: 10.3892/ol.2012.948. Epub 2012 Oct 1.
8
ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.ALK-1 蛋白表达和 ALK 基因重排有助于女性生殖道炎性肌纤维母细胞瘤的诊断。
Arch Pathol Lab Med. 2012 Jun;136(6):623-6. doi: 10.5858/arpa.2011-0341-OA.
9
Inflammatory myofibroblastic tumor of the urinary bladder diagnosed by anaplastic lymphoma kinase immunostaining.通过间变性淋巴瘤激酶免疫染色诊断的膀胱炎性肌成纤维细胞瘤
Urol Ann. 2012 May;4(2):115-8. doi: 10.4103/0974-7796.95567.
10
Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds.多阈值诊断试验的多变量随机效应荟萃分析。
BMC Med Res Methodol. 2009 Nov 10;9:73. doi: 10.1186/1471-2288-9-73.